MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FIS

/PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022....

Related Keywords

Tennessee , United States , New Jersey , Cincinnati , Ohio , America , Charlie Wood , Andy Kitzmiller , Jack Kenny , Department Of Justice , Euprotein Inc , Prnewswire Meridian Bioscience Inc , Drug Administration , Estel Biosciences Inc , Nasdaq , Sd Biosensor Inc , A Risk Factors Of The Company , Exchange Commission , Committee On Foreign Investment , Meridian Bioscience Inc , Securities Exchange , Korean Consortium , Us Department Of Justice , Fourth Quarter Fiscal , Shiga Toxin , Fiscal Year , Full Year Fiscal , Life Science , Quarter Fiscal , Chief Executive Officer , Operating Income , Chief Financial Officer , Estel Biosciences , North Brunswick , Pending Transaction , Merger Agreement , Foreign Investment , Share Data , Financial Measures , Consolidated Balance Sheet Data , Middle East , Common Share , Federal Food , Cosmetic Act , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Meridian Bioscience , United States Food , Risk Factors , Annual Report , Select Market , Nc , Health Care Amp Hospitals , Medical Pharmaceuticals , Earnings , Earnings Forecasts Amp Projections ,